MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Harrow Health Total Current Liabilities 2011-2026 | HROW
Annual Total Current Liabilities Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.3 M | 91.3 M | 49.3 M | 18.6 M | 9.72 M | 10.8 M | 12.3 M | 11.9 M | 5.77 M | 9.9 M | 5.37 M | 1.56 M | 651 K | 710 K | 1.86 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 96.3 M | 651 K | 21.7 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Pacira BioSciences
PCRX
|
310 M | $ 23.16 | -0.19 % | $ 1.07 B | USA |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.36 | 4.3 % | $ 428 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 9.84 | 2.07 % | $ 1.36 B | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.03 | -3.19 % | $ 42.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M |  Canada |
 |
Rockwell Medical
RMTI
|
16.6 M | $ 1.08 | 4.37 % | $ 25.2 M | USA |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 5.2 | 4.0 % | $ 1.9 B | Canada |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 7.1 | 6.26 % | $ 621 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.34 | - | $ 2.9 M | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
75.3 M | $ 4.44 | 0.23 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Tilray
TLRY
|
433 M | $ 7.02 | 5.45 % | $ 4.34 B | Canada |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 6.43 | 5.41 % | $ 254 M | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.92 | 2.51 % | $ 45.9 M | USA |
 |
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
5.02 M | $ 0.59 | 3.79 % | $ 10.3 M |  China |
 |
Veru
VERU
|
11.9 M | $ 2.3 | 0.44 % | $ 310 M | USA |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Viatris
VTRS
|
6.75 B | $ 13.59 | 1.72 % | $ 16.3 B | USA |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.49 | 3.31 % | $ 328 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.0 | 4.19 % | $ 108 M | Canada |
 |
cbdMD
YCBD
|
8.62 M | $ 0.79 | 2.82 % | $ 3.41 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | $ 16.81 | 1.82 % | $ 108 M | USA |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.28 | -0.44 % | $ 23.8 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |